“Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy
BACKGROUND: CD19-directed chimeric antigen receptor T-cell therapy (CART) is a life-saving regimen for children with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), yet children from lower socioeconomic and historically marginalized backgrounds are less likely to receive it. Understanding the provider experience of CART referral and post-CART clinical management is critical for designing effective interventions to improve access. OBJECTIVE: To explore physicians' experiences identifying and referring pediatric patients with r/r B-ALL for CART across diverse hospital settings, and to identify physician-perceived facilitators and barriers to CART treatment. STUDY DESIGN: Focus groups using a semi-structured guide were conducted with pediatric oncology physicians, recruited via email and at a national conference, with targeted recruitment of National Cancer Institute Community Oncology Research Program (NCORP) site providers. Questions explored identifying pediatric patients with r/r B-ALL as CART candidates, referring them for CART, and accessing institutional infrastructure to support referral. RESULTS: Analysis revealed six domains spanning referral to CART and subsequent CART treatment: identification of potentially eligible patients; complexity of CART referral; barriers to insurance approval; physician perception of patients' social/financial circumstances; and variability in pre- and post-CART management guidelines. Health system-level facilitators and barriers included patient identification and referral processes to tertiary care centers, guidelines for bridging therapy and post-CART toxicity management, and navigation support for patient care and insurance approval. CONCLUSION: Findings highlight challenges in community-based settings where resources, infrastructure and geographic availability for CART are variable. Standardizing referral pathways, centralizing trial information, and streamlining CART-center intake process and communication are of immediate importance.
Authors
- Susan Kenyon Parsons (ORCID: https://orcid.org/0000-0003-0282-6490)
- Daniel J. Zheng (ORCID: https://orcid.org/0000-0003-2217-088X)
- Kerry Q. Coughlin
- Susan R. Rheingold (ORCID: https://orcid.org/0000-0001-8025-6767)
- Haley M. Newman (ORCID: https://orcid.org/0000-0002-3022-8052)
- Allison Barz Leahy (ORCID: https://orcid.org/0000-0002-1368-4064)
- Shannon L. Maude (ORCID: https://orcid.org/0000-0003-2210-8736)
- Anna Sparrow
- Amanda M. DiNofia (ORCID: https://orcid.org/0000-0002-8321-0403)
- Sarah Kathleen Tasian (ORCID: https://orcid.org/0000-0003-1327-1662)
- Lucy E. Cain (ORCID: https://orcid.org/0000-0002-1734-2707)
- Kira O'Neil Bona (ORCID: https://orcid.org/0000-0001-5602-7059)
- Regina M. Myers (ORCID: https://orcid.org/0000-0002-2542-2061)
- Stephen A. Grupp
- Claire White
- Melissa P Beauchamin
- Colleen Kelly
Institutions
- Tufts Medical Center (US)
- Children's Hospital of Philadelphia (US)
- Harvard University (US)
- Columbia University Irving Medical Center (US)
- Penn Center for AIDS Research (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- Herbert Irving Comprehensive Cancer Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/jncics/pkag123
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Conquer Cancer Foundation
- Pennsylvania Department of Health
- Children's Hospital of Philadelphia
- National Institutes of Health
- National Cancer Institute
- National Institute on Minority Health and Health Disparities